Pfizer raised its full-year 2026 revenue forecast to $62.0 billion-$64.0 billion from $60.5 billion-$62.5 billion and increased its adjusted earnings outlook to $2.95-$3.05 per share from $2.80-$3.00. The revised earnings range includes a one-time $650 million charge related to an in-licensing and collaboration agreement with Innovent Biologics, reducing earnings by about 10 cents per share. Third-quarter adjusted earnings were 87 cents per share, unchanged from a year earlier, while revenue fell $71 million to $16.58 billion but exceeded analyst estimates of $15.87 billion from LSEG and $16.13 billion from Zacks Investment Research. Excluding Comirnaty and Paxlovid, revenue grew 7% on an operational basis, while products launched or acquired by Pfizer increased 32% to $3.8 billion. Eliquis revenue rose 25% to $2.52 billion and Padcev revenue climbed 55% to $720 million, offsetting declines in Paxlovid, Comirnaty and the Prevnar family, whose sales fell 10%. Pfizer appointed Cecile Guegan as chief financial officer and executive vice president, effective Nov. 1, after she served as interim CFO from Aug. 16. Guegan joined Pfizer after its 2009 acquisition of Wyeth and most recently oversaw finance for the Global Biopharmaceuticals division as senior vice president. She will succeed Dave Denton, who departed in August. Pfizer said its pipeline includes ongoing obesity-program development and milestones in oncology, immunology and vaccines, while Chairman and CEO Albert Bourla said the company aims for a risk-adjusted high-single-digit revenue CAGR from year-end 2028 through year-end 2033. Shares edged down 0.7% in morning trading after the results and management changes. Investors will focus on whether newer products and oncology growth can continue to offset declining COVID-19 revenue through 2027.